Enveric Biosciences, Inc. (ENVB)

NASDAQ: ENVB · Real-Time Price · USD

0.464

-0.028 (-5.63%)

At close: Nov 4, 2024, 4:00 PM

0.470

+0.006 (1.29%)

After-hours: Nov 4, 2024, 6:51 PM EST

Enveric Biosciences Employees

Enveric Biosciences had 7 employees as of December 31, 2023. The number of employees decreased by 19 or -73.08% compared to the previous year.

Employees

7

Change (1Y)

-19

Growth (1Y)

-73.08%

Revenue / Employee

n/a

Profits / Employee

-$1,513,494

Market Cap

4.14M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	7	-19	-73.08%
Dec 31, 2022	26	2	8.33%
Dec 31, 2021	24	21	700.00%
Dec 31, 2020	3	-	-

Related Stocks

Company Name	Employees
China Pharma Holdings	231
Fresh2 Group	75
Genetic Technologies	55
Oncternal Therapeutics	30
Theriva Biologics	22
Pasithea Therapeutics	8
Synaptogenix	5
Lixte Biotechnology Holdings	4

Employee Rankings

ENVB News

14 hours ago - Enveric Biosciences Announces Broad Range of Patent Issuances - Business Wire
20 days ago - Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 - Business Wire
5 weeks ago - Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop - Business Wire
5 weeks ago - Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit - Business Wire
2 months ago - Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
2 months ago - Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries' License for Treatment of Radiation Dermatitis and Other Conditions - Business Wire
3 months ago - Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results - Business Wire
3 months ago - Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally - Business Wire